ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Covid19
- Sponsor
- Centre Hospitalier de Lens
- Enrollment
- 183
- Locations
- 8
- Primary Endpoint
- mortality at day 28 and day 90.
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
COVID-19 is a worldwide pandemic. Around 5% of infected patients are admitted in ICU, mainly for respiratory failure. Outcome of these patients is linked to other organ failures. Optimal therapies are not defined so far. The sponsor want to assess the role of MR-ProADM as prognostic biomarker, and the impact of treatments (including supportive treatments) on MOF occurrence and outcome.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Any adult patient admitted in the ICU with COVID-19 pneumonia
Exclusion Criteria
- •Pregnancy
- •Legal reasons (patients under guardianship, curatorship)
- •Patient's refusal
Outcomes
Primary Outcomes
mortality at day 28 and day 90.
Time Frame: admission until day 90
mortality at day 28 and day 90.
Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.
Time Frame: comparison to day 1 and day 3
Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.
Secondary Outcomes
- Association between MR-ProADM and mortality at day 28.(admission until day 28)
- Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28.(admission until day 28)